News Drug combos from AZ, Boehringer show promise in CKD Combination regimens based on SGLT2 inhibitors and two drugs with different mechanisms of action have shown activity in patients with chronic kidney disease (CKD), raising
R&D Modelling biologics: Challenges and opportunities, with Dr D... From AAPS 2025, an interview with Dr Dhaval Shah, professor of pharmaceutical sciences at the University of Buffalo and former Pfizer researcher.
Market Access Sponsored Bridging research and clinical guidelines – interactive stra... Medical affairs is evolving. Understanding how to harness real-world data and digital insights is essential.